Oncoc4, Inc.
Clinical trials sponsored by Oncoc4, Inc., explained in plain language.
-
New combo therapy aims to control advanced prostate cancer
Disease control OngoingThis study tests a new drug combination (ONC-392 plus lutetium) in people with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. About 148 participants will receive either the combination or standard treatment to see if it helps control t…
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New hope for hard-to-treat ovarian cancer: drug duo enters phase 2 trial
Disease control OngoingThis study tests whether combining two immunotherapy drugs, ONC-392 and pembrolizumab, can shrink tumors in people with platinum-resistant ovarian cancer. About 58 adults with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer are taking part. The goal is to …
Phase: PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:24 UTC
-
New immunotherapy combo tested for tough cancers
Disease control OngoingThis early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) in a single shot. It enrolls 18 adults with various advanced solid tumors that have spread or come back. The main goal is to find the safest dose and underst…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC